Abstract
Hematopoietic progenitor cell (HPC) products contain hematopoietic stem cells, and are used to reconstitute a recipient’s bone marrow during hematopoietic stem cell transplantation. HPCs collected from bone marrow and peripheral blood by apheresis are discussed in this chapter. Hematopoietic stem and progenitor cells are identified by the cell surface antigen CD34, and enumeration of CD34+ cells is an indicator of the product’s quality. Apheresis is currently the primary source of hematopoietic stem cells. Each type of collection has advantages and disadvantages to be considered when selecting the appropriate collection method. Compared with bone marrow HPC, apheresis is easier to collect, engrafts more quickly reducing peri-transplant morbidity and mortality, contains more lymphocytes resulting in greater graft-versus-tumor effects and also a greater risk of graft-versus-host disease, and contains fewer red blood cells, thus reducing the risk of hemolytic reactions when donor and recipient are ABO incompatible.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
